Frost & Sullivan Independent Equity Research
Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2
Company: Oramed Pharmaceuticals Inc.
Report type: Initiation of Coverage
Published on: December 23, 2017